Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS: $MEDS TRxADE Group to Present at the Virtual Fall Investor Summit
TAMPA, FL, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trxade Group, Inc. ( MEDS ) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the Virtual Fall Investor Summit, hosted by Investor Summit Group and taking pl...
Got this from MEDS - TRxADE Group to Present at the Virtual Fall Investor Summit
Just In: $MEDS Trxade Group Subsidiary Bonum Health Announces Prescription Savings Partnership with SingleCare
TAMPA, FL, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Trxade Group Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, today announced that its Bonum Health subsidiary has partnered with SingleCare, the prescription savings service, to enhance Bonum’s en...
Got this from MEDS - Trxade Group Subsidiary Bonum Health Announces Prescription Savings Partnership with SingleCare
JUST IN: $MEDS Trxade Group to Present at Upcoming Investor Conferences in September
TAMPA, FL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, will participate in the following investor conferences during the month of September 2020: the Colliers Institutional Investor Conference on S...
Got this from MEDS - Trxade Group to Present at Upcoming Investor Conferences in September
NEWS: $MEDS NetworkNewsBreaks - Trxade Group Inc. (NASDAQ: MEDS) Delivers Crucial PPE, Drives Increased Revenues in Q2 2020
Trxade Group (NASDAQ: MEDS) , an integrated drug-procurement, delivery and health-care platform, achieved a record $6.6 million in revenues for the second quarter of 2020, representing a 244% increase compared to the same period last year. In large part, the company attributes the boost to a ...
Read the whole news MEDS - NetworkNewsBreaks - Trxade Group Inc. (NASDAQ: MEDS) Delivers Crucial PPE, Drives Increased Revenues in Q2 2020
News: $MEDS NetworkNewsBreaks - Trxade Group, Inc. (NASDAQ: MEDS) Announces Record Financial Results for Q2 2020
Trxade Group (NASDAQ: MEDS) , an integrated drug procurement, delivery and healthcare platform, on Monday provided its financial results for the second quarter ended June 30, 2020. Among the highlights, Trxade reported record revenues and an increase in growth profit. “The second quart...
Read the whole news MEDS - NetworkNewsBreaks - Trxade Group, Inc. (NASDAQ: MEDS) Announces Record Financial Results for Q2 2020
To Mike, sorry for your loss, Bradford has had a long and interesting life and I wish I could have listened to all the stories Bradford lived from him. If we all could have lived a great life as your father did it would be a wonderful world. Maybe you can tell me some of those moments at work some day . Your friend From Paul
The sec approved press releases is probably holding down the nice news that should be press released , if you can read between the lines in the last update and google what makes a tricorder a tricorder, Nanobeak is developing this and is probably what the China bank deal saw , even with 500 million shares outstanding VNTH should be good for a market cap of 250 million when people see it .
No one can say with absolute confidence that the Vantage sensor cannot compete with the Cannabix device , you don't even know how sensitive and accurate the vantage narcotics sensor is ,It did win the invention of the year award by NASA ,and it is used on the space station as we speak, and the sensors are being made and deployed as we speak ,so your point (no position to quickly develop ) is wrong , Vantage has a company making the sensors now not on the drawing board , and Cannabix at full throttle ,if that was true the sensor would be made and sold now, you say so many problems with the Vantage sensor yet you have not even tried one out and you never tried out the Cannabix sensor yet, and it is so far advanced ,none of your thoughts make any sense , lets sit back and watch first before we judge these two sensors , get all the facts first before we make judgements about both companies ,Cannabix could be a great sensor ,Vantage could be as great one also ,we simply don't have the facts yet. Good luck.
How will the Market react to a new Cytosorb filter, one fourth the size, and twice as potent, using a quarter less initial blood volume to start, costing twice as much, but using less filters to treat a patient,can you say a very quick double, in a heartbeat ,I can
The key , Nanobeak a wholly own subsidiary of MSGI ,how could this company become a privately held company with no filings on how this happened , does MSGI get a slice of the nanobeak pie , and how much does the shareholders get of this privately held company , will Nanobeak eventually have to go public in order for the MSGI share holders to get any monetary reimbursement , we definitely need a update on how all this went down, and who owns what, I don't want this to end up in a class action ,MEDS those stink.
Intrexon has lost half of its value since the buyout. Is the lawsuit going anywhere?
Anyone notice that Medistem cannot be found on Intrexon website other than being in press release , Medistem was on Intrexon website before the acquisition bold as life now it is acquired and nothing is there, wierd.
In the world of business greed is a good thing.
True. But XON is up over 3% today.
They managed to give out a little less shares than the estimated shares they are a greedy bunch.
Shares n cash landed..
.0385 to be exact..
Oh well we are now Intrexon shareholders lol
Does it say when it closes?
It is all here in the last PR
Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, or approximately 0.03920 shares, based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing, subject to adjustment pursuant to the terms of the merger agreement.
The proxy statement states that the price of the XON will be determined by the weighted average for 20 days following the closing of the merger. The transfer agent told me that the numbers given in the news release (and the proxy statement) were based on the Dec 19 price of XON, not the merger date. Therefore, he stated, the actual price cannot yet be determined for a few more days. (Again, I am a novice at this sort of thing and could easily be wrong)
You just take the shares you own of MEDS say 10,000 shares then you multiply by .039 and that will give you how many shares of xon you have. in this case 390 shares
Without sounding like a dunce...
Paulness can you tell us how many shares we should expect? The ratio to MEDS shares. I know it said .039 of a share based on 20 day movin avg...but i'm still lost
Well looks like the shares showed up today ,they are there but not tradable yet still pending , the cash not yet , they said a few more days.hopefully
I haven't received nothing yet. I use Etrade.
I haven't even received the shares yet..
I use tdameritrade
Did you or anyone get the cash .27 a share yet , looks like my XON shares showed up but no sign of the cash yet.
Did you get the xon shares into your account and the .27 cent a share. Still nothing
I will never understand the market..
Bunch of crooks making money off the common folk
NEWS -- Intrexon Completes Acquisition of Medistem
Date : 03/07/2014 @ 8:30AM
Source : PR Newswire (US)
Stock : Medistem, Inc. (QB) (MEDS)
GERMANTOWN, Md. and SAN DIEGO, March 7, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. (OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of these platforms, ERCs could be manufactured as genetically modified vehicles to secrete powerful therapeutic effectors in the body for clinical benefit to patients suffering from many different diseases.
In combination with Intrexon's diverse proprietary suite of technologies, including its UltraVector® gene engineering and assembly, RheoSwitch Therapeutic System® platform, and Cell Systems Informatics, Medistem's ERCs have the potential to be utilized as vehicles to deliver novel genetically controlled therapies for conditions such as cancer, inflammation, and a number of orphan diseases. Intrexon looks forward to developing these compelling technologies and making them available to existing and future collaborators.
Thomas Ichim, Ph.D., former President and Chief Science Officer of Medistem, has agreed to join the Intrexon team within its Cell Engineering Unit. Under the terms of the agreement, Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, or approximately 0.03920 shares, based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing, subject to adjustment pursuant to the terms of the merger agreement.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and the Environment to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at http://www.dna.com .
Trademarks
Intrexon, UltraVector, RheoSwitch Therapeutic System, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Intrexon Corporation or Medistem Inc. These can be identified by the use of forward-looking words, such as "believes", "expects", "may", "intends", "anticipates", "plans", "estimates", or any other analogous or similar expressions intended to identify forward-looking statements. These forward-looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this press release will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks that Medistem's ERC are capable of forming and generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung, that ERCs in combination with Intrexon's UltraVector® multi-gene engineering, proprietary Cell Systems Informatics, and RheoSwitch Therapeutic System®, Medistem's ERCs have the potential to treat acute disease conditions, such as cancer, wound healing, and cardiovascular disease or that in addition to their therapeutic benefits, ERCs could be modified to produce genes of interest.
The risks included above are not exhaustive. Other factors that could adversely affect Intrexon or Medistem's business and prospects are described in the filings made by the each Company with the SEC. The Companies expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
For more information contact:
Intrexon Corporation
Marie Rossi
Manager, Technical Communications
Tel: +1 (301) 556-9944
Email: PublicRelations@intrexon.com
SOURCE Intrexon Corporation
Copyright 2014 PR Newswire
MEDS: Company acquired by Intrexon Corporation (XON). Shareholders receive $0.27 in cash and approximately 0.03920 shares of XON per each one share of MEDS, subject to adjustment pursuant to the terms of the merger agreement. Deletion Time: 8:35:00.
http://www.otcbb.com/asp/dailylist_detail.asp?d=03/07/2014&mkt_ctg=NON-OTCBB
So they know about the lawsuits and are going ahead anyway.
Drum roll...and there's the class action, check new filings
PROPOSED SETTLEMENT OF LITIGATION
As previously disclosed on page 107 of the proxy statement/prospectus under the heading “Litigation Relating to the Merger,” Medistem, members of Medistem’s board of directors, Intrexon and Merger Sub (collectively, “Defendants”) are named as defendants in putative class action lawsuits related to the merger. Two suits have been filed in the Eighth Judicial District Court in Clark County, Nevada: Plaintiff Scott Iden (“Iden”) filed Scott Iden v. Medistem Inc., et al. , No . A-13-693813-B (the “Iden Action”), (filed December 31, 2013 and amended February 11, 2014); and plaintiff Billy D. Parent (“Parent” and together with Iden, “Plaintiffs”) filed Parent v. Medistem, Inc., et al. , No. A-14-696026-C (Dept. 31) (the “Parent Action”) (filed February 11, 2014). Several related cases against Medistem have been filed in the Superior Court for the County of San Diego, California: in the Superior Court for the County of San Diego, California, captioned as Bachand v. Medistem Inc., et al. , No. 37-2013-00081729-CU-SL-CTL (filed December 31, 2013); Parent v. Medistem Inc., et al. , No. 37-2014-00083393-CU-SL-CTL (filed January 14, 2014); and Raymond v. Medistem Inc., et al. , No. 37-2014-00083495-CU-SL-CTL (filed January 15, 2014) (collectively, the “California Actions”).
On February 18, 2014, the Business Court of Clark County, Nevada (the “Court”) granted the joint Stipulation for Consolidation and Appointment of Co-Lead Counsel and Liaison Counsel filed by the Plaintiffs and Defendants, thereby consolidating the Iden Action and the Parent Action into the case, captioned In re Medistem Inc. Stockholder Litigation , Case No. A-13-693813-B (the “Action”). The complaint (the “Consolidated Complaint”) in the Action claims that Medistem’s Board of Directors breached their fiduciary duties to Medistem by agreeing to the merger through an allegedly unfair process and for an allegedly unfair price; that Intrexon and Merger Sub aided and abetted such alleged breaches of fiduciary duty; and that the proxy statement/prospectus allegedly lacked material information necessary for Medistem’s stockholders to make an informed decision on whether to vote for or against the merger.
Paulness - You seem to know what you are doing. I am very non-savvy with OTC stocks, but I happen to own some thousands of shares of MEDS as an initial investor, since I knew Vlad, talked to Tom and understood the science. From the posts I read, especially with you and Gweet, it sounds like my best course of action is to stay where I am and hold on for whatever ride there may be. Would you suggest something else? (Past recriminations and "why did they..s" do not chart a course for action - you seem to steer that way, too)
Citellus
Smart people are buying MEDS to get XON stock at a discount , think about it you buy MEDS at 1.35 or less you get shares of XON at a 20 day average plus you get back .27 cents in cash , you can't go wrong if you want XON shares at a 20% dicount , that is what is happening now.
I see.. well let's hope someone does something
It doesn't matter if only one person sued the lawyers are going to get a good chunk of what they can get and the shareholders will get about 50% of what they collect. of course you must hold and not sell during this lawsuit , I may be wrong but that is what I heard.
Looks like Shareholder Meeting is 3/4/14.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125%2D14%2D033131%2Etxt&FilePath=%5C2014%5C02%5C03%5C&CoName=INTREXON+CORP&FormType=S%2D4&RcvdDate=2%2F3%2F2014&pdf=
I don't see much coming out of class action suit...there really isn't many stockholders in this company.
Paulness you hit that call dead on!
Once they agree to this merger and is completed, the lawyers will attack , I don't think that the CEO and CFO realise that they will get sued personally and the few shareholder that are not insiders will get money and the lawyers will make money , this was a insider self serving merger all along.
Think I just found my answer
The parties further acknowledge and agree that in no way shall such restructuring result in any change in the Cash Consideration, the Stock Consideration, the Merger Consideration or in the economics or other material terms of the transactions contemplated by this Agreement to the Company or its stockholders, or Parent, Merger Sub or their shareholders and stockholders, respectively
Cannot believe this deal didn't get reworked
Any chance todays filing is good news for us?
http://biz.yahoo.com/e/140131/meds8-k.html
VNTH - Interesting and anything that thin could run hard and fast but not sure about investing in the child company when it is the parent that has the NASA agreement? Also they still have to develop a working prototype? Will FDA approval be required?
If you have an interest in nano technology take a look at APNT and all the government research grants and the patents that they own. The new CEO has already shown that he can take a product to market so it could get real interesting with products for super efficient solar, bio-Ag, military body armor, golf clubs, hydrogen fuel tanks, thermal microprocessor cooling, etc
I also like NWBO NNVC and PSTI for long term.
What you buy is always up to you and do your DD for VNTH is a must , I have been following the CEO Jeremy Barbera for over four years from the parent company MSGI , nanobeak is now the parent company of VNTH , Jeremy use to work for NASA and that is one reason I think he got the contract, that he made some friends that allowed him the 5 year exclusive NASA contract ,MSGI was once a fortune 500 company until a korean Hyundai company ordered a lot of product but stiff MSGI on the money , it went downhill after that ,that is the reason why Mr. Barbera will produce the VNTH sensor in America only ,he learned his lesson , He knows the business and lived it and now knows what to do and what not to do .Good luck
There were a few mails you did not respond to in the past but you have no PM, i understand. No Problem, pls forget about that.
So, VNTH will GO to Dollars? Then it Must be around 3$+ cos your 2nd Rank CTSO could reach 2$+ IMO.
So Shall i try to get 100K @ 0.13-0.15 at monday?
Does NASA give you all the credibility to believe that the iPhone Lunge Cancer detection will work??
The Story is awesome but actually too good to be true.
we will see.... Thx and all the best.
SABAI
Where did you get the idea that I don't like you , If I didn't like you I would have never told you about VNTH ,I have a free account so I can't private message you , I also had INO but sold and bought VNTH and NNAN and CTSO with the profits ,I think that VNTH will do the best ,CTSO second and NNAN in third place.
Just to let you know about VNTH , they go a lock on an exclusive 5 year contract with NASA , 80% of the stock is held by insiders and the 20% left is in very strong hands ,about 140 million shares out and a product that is ready to be produced .read this below the stock is under .15 cents ,not for long !
http://www.nasdaq.com/press-release/vantage-health-receives-license-after-nasa-and-nanobeak-enter-into-an-exclusive-fiveyear-commercia-20140107-00665
Agree its a weirdo ,on another note CEO promised to get off pinks to go on OTCBB to get more value for MEDS shareholders and it would have gone up with such a low share out 15 million ,but they just did not want it to increase in value , maybe some insider got something to let it go for such a low price,a future deal with Bogin and his company ,a big job with a XON share bonus plan for the CEO, Medistem could have easily gone to $10.00 dollars , but they make this deal that is so undervalued of Medistem ,drive one absolutely nuts .
Bad enough I'm pissed about this acquisition by Intrexon, definitely not in the mood to read this garbage. I put him/her on ignore
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
508
|
Created
|
08/06/06
|
Type
|
Free
|
Moderators |
Medistem Laboratories Inc. (OTCBB: MEDS)
9255 Towne Centre Drive
Suite 450
San Diego, CA 92122
(858) 349-3617
(858) 642-0027
Company WebSite: http://www.medisteminc.com/
Contacts: thomas.ichim@medisteminc.com, Vladimir.bogin@medisteminc.com
Medistem is dedicated to commercialization of the Endometrial Regenerative Cell (ERC), a universal donor stem cell product that does not require matching with the recipient. ERC have the ability to become brain, lung, liver, bone, cartilage, pancreatic, fat, muscle, heart, and blood vessel tissue.
MediStem has discovered and filed patents on a novel type of stem cell, the Endometrial Regenerative Cell (ERC). This cell appears to have all the major attributes desirable in an ideal cellular therapy: a) Grows well and is scalable for mass production; b) Can be administered intravenously because it selectively homes to damaged tissue; c) Does not require matching with the recipient, allowing for generation of standardized batches that can be shipped to the point of care..
Medistem has filed patent applications covering a broad spectrum of stem cell manipulations and applications that has come from both its basic scientific and targeted research. While many of these could be the basis for significant licensing and development opportunities, the Company has focused on the patents surrounding its endometrial regenerative cells (ERC) (Menstrual blood cellular populations, isolation and use thereof and Endometrial derived reparative/regenerative cells). These patent applications take a multidimensional approach at protecting the Company's discoveries, covering 1) products generated from ERCs, 2) properties of the ERC products, and 3) application of the ERC products to specific disease indications.
Here's a list of MediStem's Patent Applications. Click on a link to learn more.
This application covers the composition of matter and use of a proprietary placenta derived product that is capable of expanding numerous types of stem cells both outside of the body ( ex vivo) and inside of the body (in vivo). This product is useful as a tissue culture reagent which allows for potent amplification of a patients own stem cells prior to reintroduction into the body. Another in vitro application is the utilization of this product as a research reagent which can be sold to various corporate and academic laboratories. More importantly, the ability of this product to expand stem cells in vivo implies that the major markets of hematopoiesis stimulation post chemotherapy, as well as cosmetic, rejuvenation, and antiaging markets may be addressed.
UPThis patent application covers preparations of a wide variety of stem cells and compositions useful for the treatment of cancer. The stem cells and compositions function through inducing a "guided differentiation" program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents.
UPTranscatheter chemoembolization is clinically used to treat patients with unresectable liver cancer. Our patent application teaches that by addition of a localized immune stimulus to the embolization mixture, we can use the cell death that occurs as a result of this procedure as an "endogenous vaccine" that will stimulate a systemic anti-tumor response. This is based on the fact that immunization in the liver usually results in the induction of a nonproductive immune response, but if appropriate immune stimulators are administered locally, an effective anticancer response will follow that is capable of removing tumor metastasis.
UPThis patent application covers various mechanisms by which stem cell administration can inhibit the progression of valvular dysfunction, including mitral, aortic and semilunar valve regurgitation. The non-surgical regeneration of valve structures is highly desirable in patients that are not suitable to under highly invasive interventions due to age or other factors.
UPThe size of the erectile dysfunction market is tremendous, with approximately 30 million men afflicted in the US. Despite the clinical implementation of phosphodiesterase V inhibitors (e.g. Viagra, Levitra, and Cialis), a significant percentage of patients are not responsive or suffer adverse effects from these approaches. In this patent application methods of using stem cells, and their derivatives are presented for treatment of ED.
UPThe current belief that immune suppression is needed for safety and efficacy of cord blood transplants is overcome by this patent application. The teachings of this patent, which have subsequently been published in the Journal of Translational Medicine, include methods of matching a donor with recipient so as to avoid immune mediated rejection, as well as selectively purifying the graft using clinically approved methods so as to allow for maximal stem cell activity without the need for immune suppression. This patent covers some of the technologies in the AngioStem platform.
UPThis patent application provides ways of using stem cells, including adipose tissue mononuclear cells for immune regulation. The technologies in this patent may be used for providing therapeutic solutions to a wide variety of autoimmune diseases, as well as preventing post transplant rejection.
UPThis patent application teaches the use of stem cells for treatment of lower back pain through the stimulation of endogenous biological repair processes. The patent covers several mechanisms, as well as useful cell types and compositions of matter. Back pain costs the U.S. economy over $50 billion annually and represents the second most common reason for visits to a doctor. It is estimated that 10% of 50-year-old discs and 60% of 70-year-old discs are severely degenerated.
UPThis application covers the use of various pharmaceuticals that are currently approved for the mobilization of stem cells to treat autism. The invention is based on the finding that specific compounds such as G-CSF, induce stem cells to exit the bone marrow and enter the blood stream. These stem cells appear to have activity against autism, specifically they suppress various inflammatory reactions that are found in subsets of autistic patients. Additionally, in autism, patients often display a perfusion defect in various areas of the brain such as the temporal lobe. The mobilization of stem cells is used to increase the formation of new blood vessels so as to trigger increased circulation in patients that are identified.
UPObesity is associated with numerous physiological abnormalities. In a subset of patients these abnormalities lead to altered metabolism so that even reduction in caloric intake has minimal effect on body mass. This patent application is based on clinical findings that various stem cell populations, especially derived from liposuction mononuclear cells, are capable of inducing weight-loss in subsets of patients.
UPThis patent application covers methods of using menstrual blood as a starting population of cells for isolation of numerous progenitor and stem cell subsets. The application includes various criteria for selection of cells that have specific uses. For example, in some embodiments of the invention cells are selected for high ability to make new blood vessels through isolation of populations having CD9 expression. In other embodiments the cells are selected for ability to differentiate into numerous other lineages, these populations are selected based on expression of c-kit. This application is aimed at covering the composition of matter for the starting cellular population found in the menstrual blood.
UPThis patent application covers specific regenerative cell populations found in the menstrual blood and endometrium. The cell type itself is covered, as well as uses for stimulation of healing either through direct differentiation, anti-inflammatory activity, and/or stimulation of pre-existing endogenous progenitor cells. Numerous conditions may be treated with the cells described in the patent application, these range from autoimmune diseases, to neurodegenerative diseases, to cardiac diseases. This application is of particular interest since a unique cell population is disclosed.
UPDisclosed are methods and cells useful for the improvement of insulin sensitivity in peripheral tissues. Although it is known that various types of stem cells are useful for the stimulation of insulin production, the concept of using stem cells to increase responsiveness to insulin has not been previously disclosed. The invention teaches that various adult stem cell populations, their supernatants, or various derivatives thereof, are useful for augmenting insulin receptor expression and/or downstream function of signal transduction mechanisms that are associated with insulin resistance. A further embodiment of the invention is that specific types of stem cells can trigger anti-inflammatory responses which in turn increase insulin sensitivity.
UPThe patent application provides various "adjuvants" that are useful for augmenting ability of stem cells to treat cardiovascular disorders. Some of the specific embodiments of the invention are derived from clinical observations of cardiac patients improving after combined administration of stem cells and the agents disclosed. In one embodiment intravenous anti-oxidants are using in combination with systemically delivered mesenchymal stem cells in order to enhance ventricular function.
UPThis patent application covers the treatment of autism through delivery of a population of cells possessing anti-inflammatory effects together with a population capable of stimulating angiogenesis. The invention disclosed provides specific patient subsets that may benefit from administration of stem cells such as mesenchymal and CD34 cells.
Recent News:
http://finance.yahoo.com/q?s=meds&ql=1
Medistem News Releases:
http://medisteminc.com/category/latest-buzz/news-releases/
Resources and the latest about MediStem.
Learn more about our Stem Cell Technologies.
MediStem Laboratories is a biotechnology company involved in the discovery, development, and commercialization of adult stem cell products that address serious medical conditions. We continuously evaluate our pipeline products to determine which candidates have the most promise and move those candidates towards clinical testing. Our development pipeline continues to grow, now numbering more than 8 projects for two therapeutic focus areas: vascular, and autoimmune diseases.
The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and a large proliferative capacity. A peer reviewed publication describing this novel cell type may be found at http://www.translational-medicine.com/content/5/1/57. The company is currently focusing on use of endometrial regenerative cells for treatment of critical limb ischemia, an advanced form of peripheral artery disease.
Cord blood stem cells display potent ability to generate new blood vessels. At present, the only acceptable methodology for using non-autologous cord blood cells involves immune suppression, which is associated with risks of cancer and infection. The Angiostem technology allows the selective depletion of components of cord blood that have the potential to cause immunologic rejection without depleting the cells that make new blood vessels. Since the Angiostem technology uses components that have already been approved by the FDA for other indications, we believe regulatory hurdles are markedly diminished in comparison to other cellular therapy approaches.
Angiostem derivative product candidates are being developed for the treatment of peripheral artery disease (8 million patients1), coronary artery disease (13 million patients), post stroke (15 million patients), and acceleration of wound healing (10 million patients).
Diseases of immune deregulation, called autoimmune diseases, are the third most common type of disease behind heart disease and cancer in the United States; affecting 14-22 million people. Tolerostem is a cell therapy platform that leverages naturally occurring processes to bring the immune system back into balance. The approach involves activating stem cells through specific means to upregulate their ability to generate a special type of cell called the T regulatory cell. These cells when activated are then capable of multiplying and instructing the patient's immune system to specifically stop various pathological inflammatory responses.
Tolerostem derivative product candidates are being developed for the treatment of multiple sclerosis (350,000 patients), organ rejection (250,000 patients), and rheumatoid arthritis (2.1 million patients).
About Medistem Laboratories, Inc.
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The Company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the Company believes to be non-controversial sources of stem cells. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. For more information on Medistem please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. Medistem common stock is traded on the Frankfurt, Germany stock exchange under the symbol S2U.
Recent News:
August 4, 2006 - 4:01 PM EDT
Medistem Files Patent Application for Stem Cell Therapy to Treat Erectile Dysfunction; Potential Therapy Designed to Reverse Multiple Causes of Erectile Dysfunction and Target $3 Billion Global Market for ED Treatments
Medistem Laboratories, Inc. (OTCBB:MDSM) (FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has filed a patent application with the United States Patent and Trademark Office for a potential stem cell therapy for erectile dysfunction (ED).
Medistem's potential stem cell therapy targets the market for ED drugs and other treatments. According to "Drug Store News," this market is approximately $3 billion per year. Unlike the widely prescribed ED drugs currently in use, Medistem believes the invention could address the underlying physiological causes to restore erectile function, both by inhibiting disease processes as well as through regenerative activity to ameliorate and reverse damage to blood vessels, nerves and related cells.
The number of American men suffering from erectile dysfunction is estimated to be near 30 million, according to the National Institute of Health, with an estimated 100 million patients worldwide.
"This invention is designed to treat the root causes of ED, and hopefully enable patients to restore healthy erectile abilities without having to continue taking medications," said Chris McGuinn, Vice President and Chief Operating Officer of Medistem.
Drugs called phosphodiesterase inhibitors currently dominate the market. Still, many ED sufferers are unresponsive to phosphodiesterase inhibitors, cannot tolerate the adverse side effects, or are otherwise ineligible for treatment due to heart disease and other medical conditions.
Medistem's invention contemplates the use of stem cells to restore erectile function through the treatment of various physical factors, including the regeneration of smooth muscle cells inside the penis, neural regeneration and restoration of endothelial cells lining the inside of blood vessels, and the formation of new blood vessels, among other functions.
Frequency of ED increases with age (source: Harvard School of Public Health, 2003). As the U.S. and world population ages, the percentages of men seeking ED treatment is anticipated to accelerate and spur further growth in this multi-billion dollar marketplace.
The patent application was filed in July of 2006. There can be no assurance that the patent application will be approved, or if approved, that the invention will yield a commercially viable treatment.
SHARE STRUCTURE ~~
As of March 20, 2012, the number of common shares outstanding is 6,480,440. There is no preferred stock outstanding. Because our delisting was voluntary, we will be able to relist easily when the timing for the company is right.
COMPANY LINKS ~~
Co WebSite: http://www.medisteminc.com/
SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001186519&owner=exclude&count=40
CHART: http://stockcharts.com/def/servlet/SC.web?c=meds
KNOBIAS RADiAR: http://www.knobias.com/individual/public/quote.htm?ticker=meds
MEDS - Daily Candlesticks
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |